ArticleNature communications2023

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

Takayuki Yoshino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.